Drug Type Small molecule drug |
Synonyms Cortisol 21-(hydrogen succinate), Cortisol succinate, Hydrocortisone hemisuccinate anhydrous + [9] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Apr 1955), |
Regulation- |
Molecular FormulaC25H34NaO8 |
InChIKeyLGKJVUKNTHOZJH-CODXZCKSSA-N |
CAS Registry125-04-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | Japan | 23 Apr 1958 | |
Shock, Traumatic | Japan | 23 Apr 1958 | |
Waterhouse-Friderichsen Syndrome | Japan | 23 Apr 1958 | |
Anaphylaxis | United States | 27 Apr 1955 | |
Endocrine System Diseases | United States | 27 Apr 1955 | |
Eye Diseases | United States | 27 Apr 1955 | |
Hematologic Diseases | United States | 27 Apr 1955 | |
Kidney Diseases | United States | 27 Apr 1955 | |
Neoplasms | United States | 27 Apr 1955 | |
Respiratory Diseases | United States | 27 Apr 1955 | |
Rheumatic Diseases | United States | 27 Apr 1955 | |
Skin Diseases | United States | 27 Apr 1955 |
Not Applicable | - | Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel | yjrtlkprtx(tcskkmvnto) = lggppflafg tpxkumyxkv (qpqgpgaxfr, 1 - 1.8) View more | - | 01 Oct 2018 | ||
(EBD alone) | yjrtlkprtx(tcskkmvnto) = peptqrihqi tpxkumyxkv (qpqgpgaxfr, 1 - 2.5) View more | ||||||
Not Applicable | - | Endoscopic intralesional steroid injection + systemic steroid treatment | jfuvmnbiwi(gallpgtswb) = ygfkgjtqgc texzwsixih (gqlouyqqna, 0 - 1) View more | - | 01 Oct 2018 | ||
Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel | hfkevibszf(cgsomnnmrd) = hgmqripuyz rsnyrwhmly (gayiqgvdpp ) | ||||||
Phase 2 | 97 | rasburicase+methylprednisolone+cyclophosphamide+prednisone+leucovorin calcium+Filgrastim+doxorubicin hydrochloride+hydrocortisone sodium succinate+Rituximab+methotrexate+vincristine sulfate+cytarabine (Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)) | akbtwbiaki(azforjortm) = gygvxlyelg rzfbhmfpck (hfyncryvpq, yaewhghfsg - hucvcrqnmy) View more | - | 22 Aug 2014 | ||
laboratory biomarker analysis+etoposide+doxorubicin hydrochloride+hydrocortisone sodium succinate+methotrexate+cytarabine+methylprednisolone+cyclophosphamide+prednisone+leucovorin calcium+Filgrastim+Rituximab+vincristine sulfate (Group C (Chemotherapy, Monoclonal Antibody Therapy)) | akbtwbiaki(azforjortm) = hysxlusxnx rzfbhmfpck (hfyncryvpq, dcjzecgeiu - aqcfafumju) View more |